ALK2401

ALK2401 is a small molecule, highly selective inhibitor of the voltage-gated sodium channel Nav1.8 (SCN10A), currently under development by Ailicon (Hefei) Pharmaceutical Technology for the treatment of peripheral neuropathic pain. Nav1.8 is a sodium channel primarily expressed in peripheral nociceptive neurons, where it plays a pivotal role in the generation and conduction of action potentials associated with pain signaling. By selectively targeting Nav1.8, ALK2401 aims to provide effective pain relief while avoiding the off-target effects on the central nervous system and cardiovascular system typically seen with non-selective sodium channel blockers. The drug is being evaluated in Phase I clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers.